AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18485414 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic infiltration alone (0.9% NaCl)
Number of subjects: 200
Study 16972105 — intervention group
Group type: EXPERIMENTAL
Intervention: 384 mg naltrexone base
Number of subjects: 5
Study 16972105 — intervention group
Group type: COMPARATOR
Intervention: Heroin doses (0, 6.25, 12.5, and 25 mg, i.v.)
Number of subjects: 5
Study 14521737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione (30 mg/kg) in priming fluid
Number of subjects: 20
Study 14521737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reduced glutathione)
Number of subjects: 20
Study 10764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol VII (1988-1991)
Number of subjects: 46
Study 10764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol VIII (1991-1997)
Number of subjects: 46
Study 10764156 — intervention group
Group type: COMPARATOR
Intervention: Protocol VI (1984-1988)
Number of subjects: 46
Study 10764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction/post-re-induction
Number of subjects: 46
Study 10764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CNS treatment
Number of subjects: 46
Study 10764156 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-maintenance
Number of subjects: 46
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography prescribed by family physicians
Number of subjects: 171
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous mammograms
Number of subjects: 171
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's prescription belief
Number of subjects: 171
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of mammography
Number of subjects: 171
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of time to take the test
Number of subjects: 171
Study 8616736 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 171
Study 1470390 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 plaques (intermediate, partially echogenic)
Number of subjects: 300
Study 1470390 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 plaques (highly echogenic)
Number of subjects: 300
Study 1470390 — intervention group
Group type: COMPARATOR
Intervention: Type 1 plaques (non echogenic)
Number of subjects: 300
Study 1470390 — intervention group
Group type: EXPERIMENTAL
Intervention: MR scanning
Number of subjects: 300
Study 6237662 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane via face mask
Number of subjects: 120
Study 6237662 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular blocking drugs with controlled ventilation
Number of subjects: 120
Study 30075523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 175
Study 30075523 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 175
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine5 (5 mg morphine)
Number of subjects: 90
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine10 (10 mg morphine)
Number of subjects: 90
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine15 (15 mg morphine)
Number of subjects: 90
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine5
Number of subjects: 90
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine10
Number of subjects: 90
Study 27755490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine15
Number of subjects: 90
Study 24161321 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dual antiplatelet therapy (DAPT) regimen (6 months)
Number of subjects: 224
Study 24161321 — intervention group
Group type: EXPERIMENTAL
Intervention: Long dual antiplatelet therapy (DAPT) regimen (24 months)
Number of subjects: 224
Study 24161321 — intervention group
Group type: COMPARATOR
Intervention: Short and long dual antiplatelet therapy (DAPT) regimens
Number of subjects: 224
Study 23529568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 808
Study 23529568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 808
Study 23529568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 808
Study 23529568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 20051370 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 60
Study 20051370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20051370 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic deletion of COX1 or COX2
Number of subjects: 60
Study 18624836 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL‐PDT (two sessions, 7 days apart, repeated 3 months later if incomplete clinical response)
Number of subjects: 196
Study 18624836 — intervention group
Group type: COMPARATOR
Intervention: Surgery (at baseline)
Number of subjects: 196
Study 18624836 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL‐PDT
Number of subjects: 196
Study 18624836 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 196
Study 16617757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% with 1 microg/ml fentanyl
Number of subjects: 63
Study 16617757 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with 1 microg/ml fentanyl
Number of subjects: 63
Study 16617757 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional clinical practice
Number of subjects: 63
Study 12379291 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplas
Number of subjects: 84
Study 12379291 — intervention group
Group type: COMPARATOR
Intervention: Octaplas
Number of subjects: 84
Study 10909468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine production by PBMC stimulated with mitogens for 48 hours
Number of subjects: 114
Study 10909468 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF alpha and TNF beta production
Number of subjects: 114
Study 10909468 — intervention group
Group type: COMPARATOR
Intervention: Intracellular expression of cytokines in CD4+ lymphocytes
Number of subjects: 114
Study 10909468 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of IgG and production of TNF alpha, TNF beta, and IL-10 by PBMCs
Number of subjects: 114
Study 7743569 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 micrograms.kg‐1 iv after induction of anaesthesia
Number of subjects: 215
Study 7743569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 2149514 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 30
Study 2149514 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 30
Study 2149514 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 30
Study 7030578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (0.2 to 1.6 mg/day)
Number of subjects: 28
Study 7030578 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.2 to 1.6 mg/day)
Number of subjects: 28
Study 7030578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 28
Study 7030578 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 28
Study 31935783 — intervention group
Group type: EXPERIMENTAL
Intervention: nrTMS with priming stimulation
Number of subjects: 12
Study 31935783 — intervention group
Group type: COMPARATOR
Intervention: nrTMS without priming stimulation
Number of subjects: 12
Study 30835093 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management of Dietary Intake Using Mindful Eating intervention for 6 weeks
Number of subjects: 19
Study 28562733 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration (0.75% ropivacaine) under general anesthesia
Number of subjects: 40
Study 28562733 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid block (2 ml of 0.5% bupivacaine)
Number of subjects: 40
Study 25904073 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy prescribed at ED discharge
Number of subjects: 217
Study 25904073 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive therapy prescribed
Number of subjects: 217
Study 24152240 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (30 mg for 1 week, then 60 mg for 5 weeks)
Number of subjects: 239
Study 24152240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 24152240 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 239
Study 22936078 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing emotional support to mother during illness
Number of subjects: 147
Study 22936078 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving emotional support during mother's illness
Number of subjects: 147
Study 22936078 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing emotional support to mother diagnosed with cancer no more than 5 years previously
Number of subjects: 147
Study 19668928 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) supplementation (daily, 6 days/week)
Number of subjects: 507
Study 19668928 — intervention group
Group type: COMPARATOR
Intervention: Iron only (Fe) supplementation (daily, 6 days/week)
Number of subjects: 507
Study 17615064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation (50 g/day of micronutrient fortified foods)
Number of subjects: 2800
Study 17615064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 2800
Study 17615064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation and physical exercise intervention
Number of subjects: 2800
Study 15106797 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day of water-soluble fiber from oat bran
Number of subjects: 110
Study 11290876 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 41
Study 11290876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11783254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiai Decoction (FZYAD) combined with chemotherapy
Number of subjects: 68
Study 11783254 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 68
Study 7540460 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 286
Study 7540460 — intervention group
Group type: COMPARATOR
Intervention: F-MACHOP
Number of subjects: 286
Study 2318222 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg b.i.d.)
Number of subjects: 20
Study 2318222 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg b.i.d.)
Number of subjects: 20
Study 2318222 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Felodipine and Enalapril
Number of subjects: 20
Study 368368 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol hydrochloride 2 mg, three times daily
Number of subjects: 12
Study 368368 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine sulfate 25 mg, three times daily
Number of subjects: 12
Study 31550363 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL-B score (derived from 7 variables: male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and AFP)
Number of subjects: 8048
Study 29228822 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination capsule (600 mg) containing Terminalia chebula (200 mg), Commiphora mukul (200 mg), Commiphora myrrha (200 mg) taken 3 times a day for 3 months
Number of subjects: 0
Study 29228822 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (600 mg toast powder) taken 3 times a day for 3 months
Number of subjects: 0
Study 26482687 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 and organic selenium yeast combined
Number of subjects: 443
Study 26482687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 23943825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4(+) <50 cells/µL
Number of subjects: 796
Study 23943825 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater relative 16-week increase in CD4(+) count
Number of subjects: 796
Study 23943825 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, female sex, lower BMI, higher HIV-1 RNA levels, PI and tenofovir assignment
Number of subjects: 796
Study 23943825 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation at higher CD4(+) counts
Number of subjects: 796
Study 20835732 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater omental flap (OF group)
Number of subjects: 40
Study 20835732 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OF group)
Number of subjects: 40
Study 20835732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20835732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DGE
Number of subjects: 40
Study 19052855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract
Number of subjects: 54
Study 19052855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17202200 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge system
Number of subjects: 60
Study 17202200 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge system
Number of subjects: 60
Study 12787964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosol (32mg daily for 2 weeks)
Number of subjects: 0
Study 12787964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosol (48mg daily for 2 weeks)
Number of subjects: 0
Study 12787964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosol (soft gel capsule formulation)
Number of subjects: 0
Study 12787964 — intervention group
Group type: COMPARATOR
Intervention: Glucosol (dry‐powder filled hard gelatin capsule formulation)
Number of subjects: 0
Study 10826401 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg)
Number of subjects: 429
Study 10826401 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg)
Number of subjects: 429
Study 10826401 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (12.5 to 25 mg)
Number of subjects: 429
Study 8648531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding (24-hour nasogastric feedings)
Number of subjects: 82
Study 8648531 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feeding (every 3 hours nasogastric feedings)
Number of subjects: 82
Study 8648531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding (n = 17 male neonates)
Number of subjects: 82
Study 8648531 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feeding (n = 13 male neonates)
Number of subjects: 82
Study 8648531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding
Number of subjects: 82
Study 1735869 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing headphones and listening to music
Number of subjects: 60
Study 1735869 — intervention group
Group type: COMPARATOR
Intervention: Wearing headphones but hearing no music
Number of subjects: 60
Study 1735869 — intervention group
Group type: COMPARATOR
Intervention: Control group, not wearing headphones
Number of subjects: 60
Study 6397541 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally-oriented weight loss ('diet') programme administered by professional dietitians
Number of subjects: 60
Study 6397541 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 60
Study 6397541 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally-oriented weight loss ('diet') programme
Number of subjects: 60
Study 3537101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ipodate (1 g daily for 10 days)
Number of subjects: 0
Study 3537101 — intervention group
Group type: COMPARATOR
Intervention: Saturated solution of potassium iodide (SSKI, 12 drops daily for 10 days)
Number of subjects: 0
Study 29159529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (SEV)
Number of subjects: 69
Study 29159529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27331354 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light centered at 497 nm (turquoise)
Number of subjects: 83
Study 27331354 — intervention group
Group type: COMPARATOR
Intervention: LED light centered at 459 nm (blue)
Number of subjects: 83
Study 25031274 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (100mg) plus WBRT (20 Gy in 5 fractions) followed by maintenance erlotinib (150 mg)
Number of subjects: 80
Study 25031274 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus WBRT (20 Gy in 5 fractions) followed by maintenance placebo
Number of subjects: 80
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid 10% (HF) + silane
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: CoJet + silane
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF + Metal/Zirconia Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF + Clearfil Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF + Alloy Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF + V‐Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal/Zirconia Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloy Primer
Number of subjects: 40
Study 22414522 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Primer
Number of subjects: 40
Study 19997977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atilmotin 150 microg IV
Number of subjects: 10
Study 19997977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atilmotin 30 microg IV
Number of subjects: 10
Study 19997977 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 17973974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextofisopam 200 mg b.d. for 12 weeks
Number of subjects: 140
Study 17973974 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 140
Study 17120476 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin administration
Number of subjects: 8452
Study 17120476 — intervention group
Group type: COMPARATOR
Intervention: Control (saline or no albumin/PPF)
Number of subjects: 8452
Study 12832248 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual plus group drug counseling
Number of subjects: 449
Study 12832248 — intervention group
Group type: COMPARATOR
Intervention: Other psychosocial treatments (not specified)
Number of subjects: 449
Study 10671818 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with imminent preterm labour
Number of subjects: 14
Study 10671818 — intervention group
Group type: COMPARATOR
Intervention: Healthy women with uncomplicated pregnancies
Number of subjects: 14
Study 8890876 — intervention group
Group type: EXPERIMENTAL
Intervention: Community diabetes educator presentation, video presentation, and a 4 month exercise programme
Number of subjects: 207
Study 8890876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 207
Study 2060439 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g three times daily)
Number of subjects: 60
Study 2060439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2060439 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study 6650766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of furosemide as a bolus injection at time 0 and again 6 hours later
Number of subjects: 18
Study 6650766 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg/kg per hour of furosemide as a constant infusion for 12 hours
Number of subjects: 18
Study 31276712 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent looking at food during delay of gratification task
Number of subjects: 40
Study 31276712 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent looking away from food during delay of gratification task
Number of subjects: 40
Study 29561866 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vaccination against S. aureus
Number of subjects: 7647
Study 29561866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 7647
Study 26762988 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 100 mg once a day
Number of subjects: 301
Study 26762988 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 200 mg once a day
Number of subjects: 301
Study 26762988 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 400 mg once a day
Number of subjects: 301
Study 26762988 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 301
Study 26762988 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001
Number of subjects: 301
Study 26762988 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 301
Study 23942319 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2-3.0 mg
Number of subjects: 564
Study 23942319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 23942319 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120 mg × 3 per day
Number of subjects: 564
Study 22978588 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extract (HEX) at 50 mg/kg diet
Number of subjects: 0
Study 22978588 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin (MON) at 100 mg/kg diet
Number of subjects: 0
Study 22978588 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 22978588 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extract (HEX)
Number of subjects: 0
Study 22978588 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin (MON)
Number of subjects: 0
Study 20332221 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF (Plumpy'Nut®, 1000 kcal day(‐1))
Number of subjects: 451
Study 20332221 — intervention group
Group type: COMPARATOR
Intervention: CSB pre-mix (1231 kcal day(‐1))
Number of subjects: 451